SLC22A18 and Glioma: Understanding the Connection
Author Information
Author(s): Chu Sheng-Hua, Feng Dong-Fu, Ma Yan-Bin, Zhang Hong, Zhu Zhi-An, Li Zhi-Qiang, Jiang Pu-Cha
Primary Institution: Department of Neurosurgery, NO.3 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Hypothesis
The study investigates the relationship between SLC22A18 downregulation, promoter methylation, and the development and progression of human glioma.
Conclusion
SLC22A18 downregulation via promoter methylation is associated with the development and progression of glioma, suggesting that SLC22A18 is an important tumor suppressor in glioma.
Supporting Evidence
- SLC22A18 protein expression is significantly decreased in human gliomas compared to adjacent normal brain tissues.
- SLC22A18 promoter methylation was detected in 50% of the gliomas, but not in adjacent normal tissues.
- Stable overexpression of SLC22A18 inhibited growth and adherence, and induced apoptosis in glioma cells.
Takeaway
This study found that a gene called SLC22A18 is less active in brain tumors called gliomas, which might help explain why these tumors grow and come back after treatment.
Methodology
The study examined SLC22A18 expression and promoter methylation in glioma specimens and adjacent normal tissues, using various assays including immunohistochemistry and flow cytometry.
Limitations
The study primarily focused on a specific gene and its methylation status, which may not encompass all factors influencing glioma progression.
Participant Demographics
Of the 60 patients, 45 were male and 15 were female, with an age range of 28-58 years (average 43.4 years).
Statistical Information
P-Value
p=0.000
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website